Clinical effects in a cohort of cancer patients overexposed during external beam pelvic radiotherapy.
Affiliation
Pan American Health Organization, Washington, DC, USA. cariborvas@verizon.netIssue Date
2004-06-01
Metadata
Show full item recordAbstract
PURPOSE: To evaluate the clinical outcome of 28 overexposed cancer patients in a cohort of 153 treated with pelvic irradiation and to correlate the outcome with the doses received. METHODS AND MATERIALS: Between August 2000 and March 2001, 153 patients were treated at the Instituto Oncológico Nacional of Panama with radiotherapy for cancers of the cervix, uterus, endometrium, prostate, and rectum using conventional techniques. In 56 patients, irradiated with partially blocked teletherapy fields, the treatment times were determined using a treatment planning system that generated isodose distributions. The absorbed doses received by the patients were calculated and the biologically effective doses (BEDs) and 2-Gy equivalent doses derived. The clinical outcome was evaluated using the Radiation Therapy Oncology Group (RTOG) and late effects on normal tissues-subjective, objective, management, analytic scales (LENT/SOMA). The relationships between clinical outcome and dose were investigated and compared with published data. RESULTS: Of the 56 patients for whom treatment times were generated with the treatment planning system, 28 received some doses per fraction approximately double those prescribed. Using an alpha/beta = 10 Gy, the tumor BED(10) values ranged from 77 to 225 Gy. The rest of the patients received doses within 10% of the prescribed values. Seventeen of the 28 overexposed patients died 35 days to 21 months after treatment; 13 of the fatalities were caused by rectal complications. Survival was longer in those patients who had undergone colostomy. Bladder complications were less enhanced. The nonoverexposed patients with cervical cancer exhibited a greater incidence of treatment failures than generally reported in other centers. CONCLUSION: This study provides the clinical outcome after high doses of pelvic radiotherapy in a range not previously well documented. For cervical cancer patients receiving both tele- and brachytherapy, some deaths in this overexposure cohort occurred from assumed consequential rectal injury within 2 years, when the BED(10) values exceeded 70-80 Gy. The incidence was asymptotic to 100% fatalities at >150 Gy. This confirmed and extended other data in the literature.Citation
Clinical effects in a cohort of cancer patients overexposed during external beam pelvic radiotherapy. 2004, 59 (2):538-50 Int. J. Radiat. Oncol. Biol. Phys.Journal
International Journal of Radiation Oncology, Biology, PhysicsDOI
10.1016/j.ijrobp.2003.10.024PubMed ID
15145174Type
ArticleLanguage
enISSN
0360-3016ae974a485f413a2113503eed53cd6c53
10.1016/j.ijrobp.2003.10.024
Scopus Count
Collections
Related articles
- Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix.
- Authors: Leborgne F, Fowler JF, Leborgne JH, Zubizarreta E, Chappell R
- Issue date: 1997
- Radiotherapy doses at special reference points correlate with the outcome of cervical cancer therapy.
- Authors: Yoshimura R, Hayashi K, Ayukawa F, Toda K, Iwata M, Oota S, Hoshi A, Wakatsuki M, Kurosaki H, Okazaki A, Shibuya H
- Issue date: 2008 Jul-Sep
- Comparative study of reference points by dosimetric analyses for late complications after uniform external radiotherapy and high-dose-rate brachytherapy for cervical cancer.
- Authors: Chen SW, Liang JA, Yeh LS, Yang SN, Shiau AC, Lin FJ
- Issue date: 2004 Oct 1
- Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
- Authors: Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H
- Issue date: 2005 Oct 1
- Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
- Authors: Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M, Study Group for Therapies of Rectal Malignancies (STORM)
- Issue date: 2006 Mar 15
Related items
Showing items related by title, author, creator and subject.
-
Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future.O'Brien, M; van Meerbeeck, J; Surmont, V; Faivre-Finn, Corinne (2012)
-
Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.Ingham, S; Warwick, J; Buchan, I; Sahin, S; O'Hara, Catherine; Moran, Anthony; Howell, Anthony; Evans, D; Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, UK. (2013-06)Mutations in BRCA1/2 genes confer ovarian, alongside breast, cancer risk. We examined the risk of developing ovarian cancer in BRCA1/2-positive families and if this risk is extended to BRCA negative families.
-
AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.Lillian, S; De Bono, J; Higano, C; Shapiro, G; Brugger, W; Mitchell, P; Colebrook, S; Klinowska, T; Barry, S; Dean, Emma J; et al. (2016-12)